<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816698</url>
  </required_header>
  <id_info>
    <org_study_id>GZS01167262</org_study_id>
    <nct_id>NCT01816698</nct_id>
  </id_info>
  <brief_title>Effects and Safety of Taurine Granule on Blood Pressure in Prehypertensive</brief_title>
  <acronym>ESTAB</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of TAURINE GRANULE and Placebo on Blood Pressure in Prehypertensive.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhiming Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prehypertension are associated with an increased risk of atherosclerosis and coronary artery
      disease, and often complicated with the metabolic disorder of glucose and lipid. The
      comprehensive prevention of hypertension is still an important and complex clinical issue.
      Taurine is one of the ingredients of Chinese medicine bezoar ,as an endogenous amino acids is
      central inhibitory neurotransmitter, can regulate the excitability of nerve tissue, regulate
      body temperature, therefore, antipyretic, sedative, analgesic, anti-inflammatory,the role of
      anti-rheumatic, anti-convulsant. In addition, Taurine inhibits platelet aggregation in the
      circulatory system, lower blood lipids, to maintain the body's normal blood pressure and
      prevent atherosclerosis; protective effect on myocardial cells, can be anti-arrhythmic;
      special efficacy to lower blood cholesterol, to treat heart failure. The effect of oral
      Taurine on blood pressure is not consistent, however, many animal study has shown that oral
      administration of Taurine, could reduce 24-hour mean arterial systolic and diastolic blood
      pressure in spontaneous hypertensive rats. Furthermore, Taurine interfere with calcium and
      low affinity binding of the calcium binding sites, decrease the voltage-dependent Ca2+channel
      in vascular smooth muscle relaxation, vasodilation, lower blood pressure.In a prospective,
      double-blind, randomized, and parallel-group study, we will evaluate the effects of Taurine
      granule on blood pressure and metabolic parameters in prehypertensive and mild hypertensive
      patients. This study will help develop future comprehensive prevention and treatment
      strategies for hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decrease in blood pressure after an 12-week oral Taurine granule administration.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the effects of Taurine granule on blood pressure and metabolic parameters in prehypertensive patients after an 12-week oral administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Prehypertension</condition>
  <arm_group>
    <arm_group_label>Taurine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions Drug: Taurine granule Arms: Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interventions Drug: Placebo Arms: Group 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurine granule</intervention_name>
    <description>1 package(1.6g taurine granule) once a day after meals, 12 weeks</description>
    <arm_group_label>Taurine</arm_group_label>
    <other_name>Taurine granule, H20003861.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 1 package once a day after meals, 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo packaged similar to Taurine granule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood pressure: 120mmHg≤SBP&lt;140mmHg.

        Exclusion Criteria:

          -  Diabetes

          -  Hypertension: SBP≥140mmHg, or DBP≥90mmHg.

          -  known allergy to trial drugs

          -  Myocardial infarction or cerebrovascular accident in the year preceding the trial

          -  Clinical Congestive Heart Failure

          -  Secondary hypertension

          -  Pregnancy or lactating women

          -  Malignant tumor

          -  Gastroesophageal reflux or gastroduodenal ulcer

          -  History of hepatitis or cirrhosis

          -  History of kidney disease

          -  Body weight﹤35Kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The third hospital affiliated to the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhiming Zhu</investigator_full_name>
    <investigator_title>Chief Scientist of the National Key Basic Research and Development Program (973 Program)</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Taurine</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

